(Reuters) - ViiV Healthcare, GlaxoSmithKline Plc's HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women.
from Reuters: Health News http://ift.tt/2inRGO2
No comments:
Post a Comment